Abbott Laboratories (NYSE:ABT) Stock Sale Reported by Rep. Thomas H. Kean, Jr.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on October 30th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on September 17th. The trade occurred in the Representative’s “KEAN FAMILY PARTNERSHIP” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 9/30/2026.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 9/23/2026.
• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 9/17/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 8/27/2026.
• Purchased $1,001 – $15,000 in shares of MasTec (NYSE:MTZ) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 8/10/2026.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock traded up $0.09 during trading hours on Tuesday, reaching $110.25. The stock had a trading volume of 1,259,158 shares, compared to its average volume of 11,162,896. The stock’s 50 day moving average is $104.23 and its 200 day moving average is $101.99. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $132.02. The firm has a market capitalization of $190.78 billion, a PE ratio of 41.18, a PEG ratio of 1.80 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting analysts’ consensus estimates of $1.42. The firm had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The company’s quarterly revenue was up 14.5% on a year-over-year basis. During the same period last year, the firm earned $1.30 EPS. Equities analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 94.03%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Argus lowered Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $119.00 to $127.00 in a report on Friday, October 2nd. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a report on Thursday, August 13th. Barclays initiated coverage on Abbott Laboratories in a research note on Wednesday, October 7th. They set an “overweight” rating and a $120.00 target price for the company. Finally, Robert W. Baird lifted their target price on Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $118.32.

Institutional Trading of Abbott Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Elwood & Goetz Wealth Advisory Group LLC raised its holdings in shares of Abbott Laboratories by 3.1% in the third quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 3,216 shares of the healthcare product maker’s stock valued at $318,000 after buying an additional 97 shares during the last quarter. Parkway Wealth Management Group LLC grew its holdings in shares of Abbott Laboratories by 3.2% during the third quarter. Parkway Wealth Management Group LLC now owns 3,208 shares of the healthcare product maker’s stock worth $317,000 after buying an additional 98 shares during the last quarter. Signature Equity Partners LLC grew its holdings in shares of Abbott Laboratories by 7.9% during the third quarter. Signature Equity Partners LLC now owns 1,363 shares of the healthcare product maker’s stock worth $135,000 after buying an additional 100 shares during the last quarter. St. Johns Investment Management Company LLC increased its position in Abbott Laboratories by 1.0% in the 2nd quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker’s stock valued at $895,000 after acquiring an additional 101 shares during the period. Finally, AA Financial Advisors LLC increased its position in Abbott Laboratories by 1.7% in the 3rd quarter. AA Financial Advisors LLC now owns 6,186 shares of the healthcare product maker’s stock valued at $611,000 after acquiring an additional 101 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.